en · de · es
epitalon-notes.peptides1126.com › News › Structure, Naming And Discovery — 2026 Update

Structure, Naming And Discovery — 2026 Update

By Editorial Desk · published 2025-11-10 · last reviewed 2026-01-01 · News

Everything below concerns Khavinson. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Structure, Naming and Discovery

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

Research Claims and Evidence Status

No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four constituent residues
Molecular massAbout 390.35 DaMonoisotopic value, confirmed by mass spectrometry
Residue sequenceAla-Glu-Asp-GlyRead from the N-terminus to the C-terminus
Common synonymsEpithalon; AEDGBoth forms appear in reference catalogues
Net charge near neutral pHNegativeTwo acidic side chains give a low isoelectric point

Epitalon Background and Nomenclature

The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.

Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.

Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.

Related pages on this site

Storage, Assay, and Regulatory Framework

Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.

Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Background from the literature

Modified castor oil - much like cellulose, castor oil has hydroxyl groups, unlike other oils which at most have double bonds, which castor oil also has, but most substitutions occur at the hydroxyl moieties, allowing exotic derivatives with myriad properties. The most recent advances in rheology modifiers have been in this category. The BASF corporation has a new line based on castor oil derivatives, for example. Organosilicones - Silicone resins, dimethicones, and modified silicones simplify formulation somewhat, a borrowing from cosmetics. All of the above rheology modifiers are used in the 0.2% to 2.0% range

==== Absorption ==== Doxepin is well-absorbed from the gastrointestinal tract but between 55 and 87% undergoes first-pass metabolism in the liver, resulting in a mean oral bioavailability of approximately 29%. Following a single very low dose of 6 mg, peak plasma levels of doxepin are 0.854 ng/mL (3.06 nmol/L) at 3 hours without food and 0.951 ng/mL (3.40 nmol/L) at 6 hours with food. Plasma concentrations of doxepin with antidepressant doses are far greater, ranging between 50 and 250 ng/mL (180 to 900 nmol/L). Area-under-curve levels of the drug are increased significantly when it is taken with food.

== External links == "MMR (Measles, Mumps, & Rubella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. "MMRV (Measles, Mumps, Rubella & Varicella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. Measles Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

The deep political-social divisions, as well as those between Guayaquil and Quito, prevented such an alliance from materializing (due to pro-Peruvian tendencies in Guayaquil society), however, it helped to crystallize the idea of an anti-Peruvian axis of Chile-Ecuador. At the dawn of the 20th century the situation was explosive. In June 1903, an armed conflict had already occurred between Ecuadorian and Peruvian troops in Angoteros, in the Napo River region. At the beginning of 1904, Ecuador was interested in making a common front against Peru. According to the Peruvian historian Jorge Basadre, the Ecuadorian plenipotentiary in Rio de Janeiro would have proposed that the Brazilian baron of Rio Branco accept the cession of part of the territory that his country disputed to Peru so that Brazil could obtain an exit to the Pacific, the cession was mainly considered from Tumbes. Naturally, such territorial expansion could only be obtained by a war that, in truth, was not in the Baron's plans. The crucial point for him was just to guarantee possession of Acre without making new concessions to Peru. After the arbitration award of the King of Spain, who at that time was the Bourbon Alfonso XIII, faced with the prospect of a war between Peru and Ecuador, which would have caused the ruling, refrained from the Peruvian-Ecuadorian tension of 1910.

== Research use == Since C. hemisphaerica passes through planula, polyp, and medusa stages during its life cycle, it is regarded as a good model for studying how one genome can produce variable phenotypes. This is especially useful when considering that two of the more common Cnidarian model organisms, Hydra and Nematostella, do not have the same "complete' life-cycle that alternates between a vegetative polyp and sexually reproducing, free-swimming medusa form. Clytia has characteristics that make it favorable for laboratory culture and experimental manipulation. All stages of Clytia's life cycle can be reproduced under laboratory conditions; polyp colonies, due to their essentially immortal nature, are easily maintained, and adult medusa can be fed with Artemia larvae. Adult male and female medusa spawn daily, and can be entrained with controlled light conditions to spawn at specific times. The oocytes, eggs, embryos, and planulae of Clytia are easily visualized under a microscope and, much like those of popular model organisms like sea urchins, the zygotes of C. hemisphaerica are relatively large (around 200 um in diameter) and can be microinjected to form transgenic planulae, polyp colonies, and medusa. Clytia is also unique in that its gonads can function autonomously; a gonad separated from an adult medusa will undergo oocyte development and ovulation under the same entrained light cues as would a gonad still attached to a medusa.

Sources: en.wikipedia.org

Reference notes

== Historical uses == Especially in medieval times, the end of a chain could be attached to a chain tower or boom tower. This allowed safe raising or lowering of the chain, as they were often heavily fortified. By raising or lowering a chain or boom, access could be selectively granted rather than simply rendering the stretch of water completely inaccessible. The raising and lowering could be accomplished by a windlass mechanism or a capstan. Booms or chains could be broken by a sufficiently large or heavy ship, and this occurred on many occasions, including the siege of Damietta, the raid on the Medway and the Battle of Vigo Bay.A Frequently, however, attackers instead seized the defences and cut the chain or boom by more conventional methods. The boom at the siege of Derry, for example, was cut by sailors in a longboat. As a key portion of defences, booms were usually heavily defended. This involved shore-based chain towers, artillery batteries, or forts. In the Age of Sail, a boom protecting a harbour could have several ships defending it with their broadsides, discouraging assaults on the boom. On some occasions, multiple booms spanned a single stretch of water.

Trump also signed an executive order attempting to end birthright citizenship for children of unauthorized immigrants as well as immigrants legally but temporarily present in the United States. At least nine lawsuits have been filed challenging the order on constitutional grounds, and as of February 2025, four federal judges have issued preliminary injunctions blocking its implementation and enforcement nationwide. On June 27, the Supreme Court limited the ability of individual District Judges to issue injunctions against executive actions, meaning to pause executive action. The Supreme Court did not rule on the merits of birthright citizenship. District Judges can still issue injunctions in limited circumstances, such as for persons directly involved in a class action lawsuit. On January 22, 2025, Trump ended the policy from 2011 which prohibited immigration arrests in sensitive areas such as courthouses, schools, churches, and hospitals, or during funerals and weddings. NPR reported that a "growing number" of Democrat and Republican officials in cities, states, police departments, school districts and other local governments stated they would not assist in migrant raids citing public safety, civil rights, and administrative capability concerns. On January 29, Trump signed the Laken Riley Act into law, the first legislation of his second term. On the same day, he signed a presidential memorandum to begin expansion of the Guantanamo Migrant Operations Center to house up to 30,000 migrants under detention, separate from the high security military prison at Guantanamo Bay.

=== SB Pharmco Puerto Rico === In 2010, the US Department of Justice announced that GSK would pay a US$150 million criminal fine and forfeiture, and a civil settlement of US$600 million under the False Claims Act. The fines stemmed from production of improperly made and adulterated drugs from 2001 to 2005, at GSK's subsidiary, SB Pharmco Puerto Rico Inc., in Cidra, Puerto Rico, which at the time produced US$5.5 billion of products each year. The drugs involved were Kytril, an antiemetic; Bactroban, used to treat skin infections; Paxil, the anti-depressant; and Avandamet, a diabetes drug. GSK closed the factory in 2009. The case began in 2002, when GSK sent experts to fix problems cited by the FDA. The lead inspector recommended recalls of defective products, but they were not authorised; she was fired in 2003, and filed a whistleblower lawsuit. In 2005, federal marshals seized US$2 billion worth of products, the largest such seizure in history. In the 2010 settlement SB Pharmco pleaded guilty to criminal charges, and agreed to pay US$150 million in a criminal fine and forfeiture, at that time the largest such payment ever by a manufacturer of adulterated drugs, and US$600 million in civil penalties to settle the civil lawsuit.

== Biosynthesis == The production of bottromycin by S. bottropensis and S. scabies, as well as the production of a bottromycin analog termed bottromycin D, has been studied. It was independently confirmed in 2012 by multiple groups that bottromycin is produced as a ribosomal peptide natural product that it subsequently post-translationally modified. Before this, it was unclear whether bottromycin was produced by nonribosomal peptide synthetase machinery (NRPS). The presence of amino acids other than the 20 proteinogenic amino acids is often a feature of NRPS products because NRPS machinery can directly incorporate other amino acids, among other chemical building blocks. Ribosomal peptide synthesis, which is the same machinery that produces all proteins found in the cell, is limited to the 20 proteinogenic amino acids. However, bottromycin was found to be a highly modified ribosomal peptide by a combination of genome mining and gene deletion studies. In ribosomal peptide synthesis, the final product results from modifications to a linear peptide starting material translated by the ribosome from an mRNA transcript. In S. scabies the precursor peptide, termed BtmD, is a 44-amino acid peptide. The precursor peptide is termed BmbC in S. bottropensis. The amino acids forming the bottromycin core are residues 2-9 in BtmD: Gly-Pro-Val-Val-Val-Phe-Asp-Cys. In bottromycin D, the sequence is Gly-Pro-Ala-Val-Val-Phe-Asp-Cys, and the precursor peptide is termed BstA. BstA shares high sequence homology with BtmD in the follower peptide region.

Sources: en.wikipedia.org

Reference notes

Subjects may experience extreme confusion and/or a depressed mood. The visionary stage typically lasts 4–8 hours, but may last longer with especially high doses. The introspective phase is poorly defined, often simply as 24 or 36 hours post-treatment. Sensation and perception return to normal, but nausea, headaches, and other side effects linger. Insomnia, irritability, and mood changes are often seen, including depression and sometimes mania. Depression can persist well after 36 hours, known as a "grey day"; the effect is well-recognized. A persistently low mood can progress into major depressive disorder, a chronic condition. For the treatment of opioid or alcohol addiction, the subjective experiences do not appear to be important, although they are correlated with some secondary measures (e.g., satisfaction in self-assessments). Ibogaine has been referred to as an oneirogen (oneirophrenic or oneiric), or a hallucinogen that produces a dream-like state of consciousness. This unique altered state of consciousness is shared with harmala alkaloids like harmaline but is distinct from that of other hallucinogens like serotonergic psychedelics such as LSD or psilocybin.

== See also == Bush tax cuts – Changes to the United States tax code during the Bush presidency Omnibus spending bill – Type of appropriations bill Tax reform – Method of changing compulsory fees or levies as part of broad economic programmes

In August 2026, Disney and TikTok announced a content-sharing partnership that will allow participating TikTok creators to use approved material from Disney films and television programs in their videos. Selected creator videos will also be featured within Disney+ through its Verts mobile video section. The initiative includes content related to Disney properties such as Marvel, Star Wars, Pixar, and FX, and is expected to begin as a pilot in the United States before potentially expanding to other markets.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.

Are epitalon and epithalon different compounds?

No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.

How does epitalon differ from epithalamin?

Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

Network